Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that boosting the synthesis of neural-derived 17β-estradiol effectively counteracted the impairment of hippocampal long-term potentiation caused by amyloid beta 1-42 in rat hippocampal slices, with the effect seemingly linked to glutamate NMDAR signaling.

This review highlights advances in understanding trichotillomania's neurobiology and treatment, noting behavior therapy's effectiveness and new pharmacological and digital therapies, while addressing underdiagnosis, stigma, and research gaps.

This study demonstrates that massage significantly enhances the follicular targeting of dutasteride-loaded nanocapsules, increasing drug accumulation in hair follicles by up to 5 times.

In this clinical study, researchers reported that both sodium valproate-loaded nanospanlastics and topical corticosteroids showed comparable modest efficacy in treating patchy alopecia areata, recommending further investigation into sodium valproate's role combined with other therapies.

This article reviews the synthesis and properties of isotretinoin, tazarotene, minoxidil, and finasteride, and reports no new findings.

This correction clarifies the affiliations of researcher D. Piomelli in a case report on symptom improvement in a chronic psychotic patient treated with finasteride, without presenting new research findings.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This study found that dutasteride increased hair growth metrics significantly more than finasteride in Korean men with AGA, but a meta-analysis suggests no overall significant efficacy difference between the two drugs.

This study discusses levetiracetam's role as an alternative treatment for idiopathic generalized epilepsies, highlighting its potential effectiveness, especially for patients unsuitable for valproate.

This study found that in hirsute women, daily treatment with 200 mg spironolactone significantly reduced hair growth rates and hair shaft diameters on various body areas over 12 months.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This study found that spironolactone reduced hirsutism scores in women without significant hormonal changes, suggesting its effectiveness primarily through peripheral mechanisms.

This study found that minoxidil prevents long-term serotonergic toxicity induced by MDMA in rats, primarily by opening mitochondrial KATP channels and involving Akt and MAP kinases in its neuroprotective mechanism.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study found that men taking 1 mg/day of finasteride had significantly reduced sperm production and morphology but similar hormonal, sexual, and psychological profiles compared to controls, suggesting finasteride affects semen quality without altering other physiological functions.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.

This study demonstrated that benzothiazepines, such as diltiazem and JTV-519, exert anxiolytic-like effects through allopregnanolone biosynthesis in mice, similar to carbamazepine.

In this study, young adult male albino rats treated with finasteride showed a 10% reduction in thickness of the CA1 layer of the hippocampus, suggesting that this atrophy may contribute to memory impairments linked to Post-Finasteride Syndrome.

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

This study reviews the psychological side effects of finasteride, noting a potential association between 5-AR inhibitors and increased depressive symptoms, but emphasizes that the causal link to suicidal ideation remains unclear; the authors recommend mental health screenings and close monitoring for patients starting this medication.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that repeated finasteride administration in male Wistar rats led to increased depression-like behavior, suggesting an animal model for investigating finasteride's neuropsychiatric effects is viable.

This case study highlights an adolescent girl with atypical anorexia nervosa who experienced mental health changes after using semaglutide, underscoring the need for cautious prescription and follow-up of this medication to prevent adverse effects in vulnerable individuals.

Spironolactone reduces hair growth in women with unexplained excessive hairiness.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.